Literature DB >> 22510702

PET/CT and contrast enhanced CT in single vs. two separate sessions: a cost analysis study.

M Picchio1, M Mansueto, C Crivellaro, L Guerra, S Marcelli, M Arosio, S Sironi, L Gianolli, A Grimaldi, C Messa.   

Abstract

AIM: Aim of the study was to quantify the economic impact of PET/CT and contrast enhanced (c.e.) CT performed in a single session examination vs. stand-alone modalities in oncological patients.
METHODS: One-hundred-forty-five cancer patients referred to both PET/CT and c.e. CT, to either stage (N.=46) or re-stage (N.=99) the disease, were included. Seventy-two/145 performed both studies in a single session (innovative method) and 73/145 in two different sessions (traditional method). The cost-minimization analysis was performed by evaluating: 1) institutional costs, data obtained by hospital accountability (staff, medical materials, equipment maintenance and depreciation, departments utilities); 2) patients costs, data obtained by a specific survey provided to patients (travel, food, accommodation costs, productivity loss).
RESULTS: Economic data analysis showed that the costs for innovative method was lower than those of traditional method, both for Institution (106 € less per test) and for patient (21 € less per patient). The loss of productivity for patient and caregivers resulted lower for the innovative method than the traditional method (3 work-hour less per person).
CONCLUSION: PET/CT and c.e. CT performed in a single session is more cost-effective than stand-alone modalities, by reducing both Institutional and patients costs. These advantages are mainly due to lower Institutional cost (single procedure) and to lower cost related to travel and housing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510702

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  1 in total

Review 1.  PET/MR: a paradigm shift.

Authors:  Florian C Gaertner; Sebastian Fürst; Markus Schwaiger
Journal:  Cancer Imaging       Date:  2013-02-27       Impact factor: 3.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.